Sandoz receives exclusive rights from Biocon Biologics to market biosimilar adalimumab in Japan

26 Dec 2023 , 10:55 AM

A Biocon subsidiary called Biocon Biologics announced on Friday that it has reached a deal with Sandoz that gives the latter the only right to market, sell, and distribute the biosimilar drug Adalimumab for subcutaneous injection in Japan.

The transaction’s financial specifics were kept under wraps.

Adalimumab and the rest of Viatris’ global biosimilars portfolio have been bought by Biocon Biologics. The drug’s creator, Fujifilm Kyowa Kirin Biologics Co. Ltd., and an associate of Biocon Biologics Ltd. have reached an exclusive global marketing licence deal.

In accordance with this agreement, Viatris will cease product marketing and promotion on December 15, 2023, but will go on with transition support until Sandoz gradually takes over on February 15, 2024.

Adalimumab BS, a subcutaneous injectable biosimilar to Humira, is prescribed for immune-related conditions like ulcerative colitis, psoriasis vulgaris, ankylosing spondylitis, rheumatoid arthritis, and Crohn’s disease.

The market for biosimilar adalimumab is expected to be worth $613.28 million in 2022 and expand at a compound annual growth rate (CAGR) of 23.2 percent from 2023 to 2031, or $3954.75 million.

An important step forward in the company’s development into a fully integrated, international biosimilars operation, Biocon Biologics recently announced the successful completion of its integration of the biosimilars business of Viatris, which it had purchased, in 120 countries ahead of schedule.

For feedback and suggestions, write to us at [e-mail]